中华传染病杂志
中華傳染病雜誌
중화전염병잡지
CHINESE JOURNAL OF INFECTIOUS DISEASES
2010年
5期
286-289
,共4页
肝炎,乙型,慢性%多态现象,遗传%启动区(遗传学)%干扰素α%受体,干扰素%基因型
肝炎,乙型,慢性%多態現象,遺傳%啟動區(遺傳學)%榦擾素α%受體,榦擾素%基因型
간염,을형,만성%다태현상,유전%계동구(유전학)%간우소α%수체,간우소%기인형
Hepatitis B,chronic%Polymorphism,genetic%Promoter regions (genetics)%Interferon-alpha%Receptors,interferon%Genotype
目的 探讨慢性乙型肝炎患者的Ⅰ型干扰素受体1(IFNAR1)基因启动子多态性和IFN-α治疗应答之间的关系.方法 选择接受IFN-α治疗的慢性乙型肝炎患者61例,采用重组IFN-α2b 500万U,隔天肌内注射,疗程48周,观察应答情况,对入选患者的IFNAR1基因启动子区进行测序,计量资料采用t检验,计数资料采用卡方检验.结果 治疗的慢性乙型肝炎患者中,完全应答22例,部分应答8例,无应答31例.IFNAR1基因启动子区一408C/T、-3C/T、-77GT双核苷酸重复序列[-77(GT),]存在基因多态性,这三个位点基因多态性存在连锁,形成-408C/-77(GT)5/-3C等基因单体型.IFNAR1启动子区基因型为-408C/-77(GT)5/-3C及-408C/-77(GT)5/-3C的,基因型为-408C/-77(GT)5/-3C和非-408C/-77(GT)5/-3C的慢性乙型肝炎患者对IFN-α的应答率为61.0%,高于基因型为非-408C/-77(GT)5/-3C,非-408C/-77(GT)5/-3C患者的25.0%(X2=6.961,P=0.008).结论 IFNAR1启动子基因型为-408C/-77(GT)5/-3C及-408C/-77(GT)5/-3C的,-408C/-77(GT)5/-3C和非-408C/-77(GT)5/-3C的慢性乙型肝炎患者对IFN-α治疗应答较好,IFNAR1基因启动子多态性与慢性乙型肝炎患者的干扰素应答有关.
目的 探討慢性乙型肝炎患者的Ⅰ型榦擾素受體1(IFNAR1)基因啟動子多態性和IFN-α治療應答之間的關繫.方法 選擇接受IFN-α治療的慢性乙型肝炎患者61例,採用重組IFN-α2b 500萬U,隔天肌內註射,療程48週,觀察應答情況,對入選患者的IFNAR1基因啟動子區進行測序,計量資料採用t檢驗,計數資料採用卡方檢驗.結果 治療的慢性乙型肝炎患者中,完全應答22例,部分應答8例,無應答31例.IFNAR1基因啟動子區一408C/T、-3C/T、-77GT雙覈苷痠重複序列[-77(GT),]存在基因多態性,這三箇位點基因多態性存在連鎖,形成-408C/-77(GT)5/-3C等基因單體型.IFNAR1啟動子區基因型為-408C/-77(GT)5/-3C及-408C/-77(GT)5/-3C的,基因型為-408C/-77(GT)5/-3C和非-408C/-77(GT)5/-3C的慢性乙型肝炎患者對IFN-α的應答率為61.0%,高于基因型為非-408C/-77(GT)5/-3C,非-408C/-77(GT)5/-3C患者的25.0%(X2=6.961,P=0.008).結論 IFNAR1啟動子基因型為-408C/-77(GT)5/-3C及-408C/-77(GT)5/-3C的,-408C/-77(GT)5/-3C和非-408C/-77(GT)5/-3C的慢性乙型肝炎患者對IFN-α治療應答較好,IFNAR1基因啟動子多態性與慢性乙型肝炎患者的榦擾素應答有關.
목적 탐토만성을형간염환자적Ⅰ형간우소수체1(IFNAR1)기인계동자다태성화IFN-α치료응답지간적관계.방법 선택접수IFN-α치료적만성을형간염환자61례,채용중조IFN-α2b 500만U,격천기내주사,료정48주,관찰응답정황,대입선환자적IFNAR1기인계동자구진행측서,계량자료채용t검험,계수자료채용잡방검험.결과 치료적만성을형간염환자중,완전응답22례,부분응답8례,무응답31례.IFNAR1기인계동자구일408C/T、-3C/T、-77GT쌍핵감산중복서렬[-77(GT),]존재기인다태성,저삼개위점기인다태성존재련쇄,형성-408C/-77(GT)5/-3C등기인단체형.IFNAR1계동자구기인형위-408C/-77(GT)5/-3C급-408C/-77(GT)5/-3C적,기인형위-408C/-77(GT)5/-3C화비-408C/-77(GT)5/-3C적만성을형간염환자대IFN-α적응답솔위61.0%,고우기인형위비-408C/-77(GT)5/-3C,비-408C/-77(GT)5/-3C환자적25.0%(X2=6.961,P=0.008).결론 IFNAR1계동자기인형위-408C/-77(GT)5/-3C급-408C/-77(GT)5/-3C적,-408C/-77(GT)5/-3C화비-408C/-77(GT)5/-3C적만성을형간염환자대IFN-α치료응답교호,IFNAR1기인계동자다태성여만성을형간염환자적간우소응답유관.
Objective To investigate the association between promoter polymorphisms of interferon-alpha receptor-1 (IFNAR1) gene and the treatment response to interferon-alpha (IFN-α) in patients with chronic hepatitis B (CHB). Methods Sixty-one CHB patients who consented to receive IFN-a therapy were enrolled in this study. The subjects were treated with recombinant IFN-α2b 500 MU intramuscular injection qod for 48 weeks. The treatment responses were monitored.Meanwhile, the promoters of IFNAR1 gene in these patients were sequenced. Measurement data were analyzed by t test and enumeration data were analyzed by Chi square test. Results Twenty-two treated patients achieved complete response. Eight patients achieved partial response and 31 had no response. Polymorphisms were identified in the promoter of IFNAR1 gene, which included C/T substitution at locus -408, C/T substitution at locus-3 and GT microsatellite repeat sequence at locus-77 [-77(GT)n]. The three polymorphisms were in linkage and composed some haplotypes,such as - 408C/-77(GT)5/-3C. The response rate to IFN-α in CHB patients with genotypes -408C/-77(GT)5/-3C, -408C/-77(GT)5/-3C, and-408C/-77(GT)5/-3C, non -408C/ - 77(GT)5/-3C in IFNAR1 gene promoter was higher than that in patients with genotype non -408C/-77(GT)5/-3C, non-408C/- 77(GT)5/- 3C (61. 0% vs 25. 0%, x2=6. 961, P =0.008). Conclusions CHB patients with genotype-408C/ - 77(GT)5/ - 3C, -408C/-77(GT)5/-3C and -408C/ -77(GT)5/ -3C, non -408C/ -77(GT)5/-3C in the promoter of the IFNAR1 gene are prone to have better response to IFN-a treatment. Polymorphisms in the promoter of IFN-αgene are associated with the treatment response to IFN-α in CHB patients.
